Global COVID-19 vaccine inequity: The scope, the impact, and the challenges

Archana Asundi; Colin O'Leary; Nahid Bhadelia

doi:10.1016/j.chom.2021.06.007

Global COVID-19 vaccine inequity: The scope, the impact, and the challenges

Cell Host Microbe. 2021 Jul 14;29(7):1036-1039. doi: 10.1016/j.chom.2021.06.007.

Authors

Archana Asundi¹, Colin O'Leary², Nahid Bhadelia³

Affiliations

¹ Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA; Section of Infectious Diseases, Boston Medical Center, Boston, MA 02118, USA.
² Program in Virology, Harvard Medical School, Boston, MA 02115, USA.
³ Section of Infectious Diseases, Boston Medical Center, Boston, MA 02118, USA; Center for Emerging Infectious Diseases Policy and Research (CEID), Boston, MA 02118, USA; National Emerging Infectious Diseases Laboratories (NEIDL), Boston, MA 02118, USA. Electronic address: nbhadeli@bu.edu.

Abstract

Global vaccine inequity is prolonging the COVID-19 pandemic. Here, we outline the scope and impact of inequitable vaccine distribution and identify challenges in vaccine development, manufacturing, and distribution as well as potential solutions to address this crisis.

MeSH terms

Biomedical Research
COVID-19 / prevention & control*
COVID-19 Vaccines / standards
COVID-19 Vaccines / supply & distribution*
China
Humans
Manufacturing and Industrial Facilities
Pandemics / prevention & control*
SARS-CoV-2
United States
United States Food and Drug Administration
Vaccination

Substances

COVID-19 Vaccines